Evidence map›Paper›PMID 41946315›Full record

ArticleBiomaterials2026

Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.

Enya Li, Nina Butkovich, Jo A Tucker, Edward L Nelson, Szu-Wen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Enya LiDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, USA.
Nina ButkovichDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, USA.
Jo A TuckerDepartment of Medicine, University of California, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.
Edward L NelsonDepartment of Medicine, University of California, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA; Institute for Immunology, University of California, Irvine, CA 92697, USA.
Szu-Wen WangDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA; Department of Biomedical Engineering, University of California, Irvine, CA 92697, USA; Institute for Immunology, University of California, Irvine, CA 92697, USA. Electronic address: wangsw@uci.edu.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined ImmunotherapyR01EB027797 · NIBIB · UNIVERSITY OF CALIFORNIA-IRVINE · PI WANG, SZU-WEN · 2019 to 2022
$1.3M
NCI NIH HHS P30 CA062203NIBIB NIH HHS R01 EB027797
6 · The paper itself

Abstract

Nanoparticle (NP)-based cancer vaccine therapies conventionally incorporate tumor-associated antigens or neoantigens that are major histocompatibility complex (MHC) class I-restricted, an approach that educates cytotoxic CD8

Indexed as

Cancer VaccinesHistocompatibility Antigens Class IHistocompatibility Antigens Class IINanoparticlesT-LymphocytesAnimalsAntigens, NeoplasmCell Line, TumorFemaleMiceMice, Inbred C57BLNanovaccinesAntigens, NeoplasmCancer VaccinesHistocompatibility Antigens Class IHistocompatibility Antigens Class IINanovaccinesAntigensCancer vaccinesMHC class IMHC class IINanoparticlesT cells

Identifiers

PMID41946315
PMCPMC13249364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.